Ensysce Biosciences, Inc.
ENSC
$0.47
$0.000.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -39.29% | -24.36% | -2.75% | 1.51% | 415.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.29% | -24.36% | -2.75% | 1.51% | 415.60% |
| Cost of Revenue | 33.16% | 42.18% | 43.73% | 87.03% | 58.36% |
| Gross Profit | -317.55% | -239.22% | -164.27% | -394.96% | 57.42% |
| SG&A Expenses | 0.30% | -1.00% | 4.45% | -2.44% | -8.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.03% | 26.49% | 28.20% | 44.67% | 26.71% |
| Operating Income | -90.40% | -72.66% | -52.16% | -74.91% | 31.17% |
| Income Before Tax | -91.81% | -72.93% | -27.40% | -38.42% | 41.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.81% | -72.93% | -27.40% | -38.42% | 41.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 150.00% | -- | 400.00% | -81.82% | -91.30% |
| Net Income | -91.80% | -72.92% | -27.40% | -38.43% | 41.64% |
| EBIT | -90.40% | -72.66% | -52.16% | -74.91% | 31.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 32.24% | 49.50% | 68.65% | 76.85% | 90.21% |
| Normalized Basic EPS | 32.24% | 49.51% | 68.65% | 76.84% | 90.20% |
| EPS Diluted | 32.24% | 49.50% | 68.65% | 76.85% | 90.21% |
| Normalized Diluted EPS | 32.24% | 49.51% | 68.65% | 76.84% | 90.20% |
| Average Basic Shares Outstanding | 381.64% | 302.80% | 256.44% | 320.98% | 298.02% |
| Average Diluted Shares Outstanding | 381.64% | 302.80% | 256.44% | 320.98% | 298.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |